HZNP earnings call for the period ending December 31, 2019.
News & Analysis: Horizon Therapeutics
Shares are up 4% following the announcement.
First FDA-approved medicine for thyroid eye disease.
Patients with this rare condition can now get relief for their symptoms.
An FDA panel’s vote lifted Horizon’s shares, but a steady rally will depend on the FDA’s approval decision.
With FDA approval deadlines approaching in 2020, these four drug developers could see substantial gains if they're successful.
HZNP earnings call for the period ending September 30, 2019.
HZNP earnings call for the period ending June 30, 2019.
Strong growth for its orphan, rheumatology, and primary care drugs translated to a great first quarter for Horizon.
HZNP earnings call for the period ending March 31, 2019.